David A. Scheinberg

26.1k citations

304 papers · 17.9k indexed · 5 hit papers · h-index 72

Impact in

Hematology top 0.1%
- Acute Myeloid Leukemia Research
Radiology, Nuclear Medicine and Imaging top 0.1%
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging Techniques and Applications

Papers in

Radiology, Nuclear Medicine and Imaging 131
- Radiopharmaceutical Chemistry and Applications 83
- Monoclonal and Polyclonal Antibodies Research 81
Oncology 123
- CAR-T cell therapy research 61
- Peptidase Inhibition and Analysis 22

Co-authors: Michael R. McDevitt Joseph G. Jurcic Raymond P. Warrell Ronald D. Finn George Sgouros Janice Gabrilove Steven M. Larson Dangshe Ma
Journals: Blood (38 papers)Journal of Clinical Oncology (15 papers)PLoS ONE (8 papers)Clinical Cancer Research (8 papers)OncoImmunology (6 papers)
Partner nations: United States Germany Canada

In The Last Decade

David A. Scheinberg

295 papers receiving 17.3k citations

Hit Papers

5 papers align trajectories log scale

Acute myeloid leukaemia 2016 · 289 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Nature Reviews Disease Primers
2003 JAMA
2001 Journal of Clinical Oncology
1998 New England Journal of Medicine
1991 New England Journal of Medicine

Peers

Countries citing papers authored by David A. Scheinberg

Since Specialization

Citations

This map shows the geographic impact of David A. Scheinberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Scheinberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Scheinberg more than expected).

Fields of papers citing papers by David A. Scheinberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Scheinberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Scheinberg. The network helps show where David A. Scheinberg may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David A. Scheinberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Scheinberg Line = papers co-authored together David A. Scheinberg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity Science Advances ·L. E. Price, Pedro C. Silberman, P. Boltizár, James E. Han, 清一郎釘崎, Н.А. Буданцева, Daniel A. Heller, David A. Scheinberg	2025	6
2	Tumor microenvironment–targeted PROTAC nanoparticle self-assembly broadly predicted by structural descriptors Science Advances ·L. E. Price, S.-Y. Lee, Mandana T. Manzari, 岸本恭, Irene Vänninen, Xufen Yu, Thornton Boyd, Quincey LaPlant, Veikko Marttila, G. Praveen Raju, Jian Jin, David A. Scheinberg, Daniel A. Heller	2025	0
3	A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity PLoS ONE ·Cherie E Saffold, Irina V. Lebedeva, Emma Zilberman, 肖霞云, S. A. Braim, Valdir Skrzypczak, Olivia Vergnolle, Leyi Shen, Calzada Nova, Manuel Baca, David A. Scheinberg	2025	0
4	Design of high-specificity binders for peptide–MHC-I complexes Science ·Bingxu Liu, Gabriela Vladu, Riham Aljafari, 西嶋尚彦, A. Camilli, Tao Dao, Xinyu Xiang, Russell Ault, J. M. Sharp, Chunyu Wang, پویا جودی گللر, Dionne Vafeados, В А Тихонов, Armita Nourmohammad, David A. Scheinberg, K. Christopher García, David Baker	2025	5
5	Augmenting CAR T-cell Functions with LIGHT Cancer Immunology Research ·Asw Lee, D.L. Richards, Xiaoli Mi, Vinagolu K. Rajasekhar, Ivan Conrado Šoštarić Zuckermann, Sarah Yoo, Elisa de Stanchina, Jahan Rahman, S Mathew, Cristine Roussel, Gloria Rebeca Vela Romo, R Zahnert, Josefin Fransén, A. Camilli, Anna Ramon Aribau, John H. Healey, Omar Abdel‐Wahab, David A. Scheinberg, Renier J. Brentjens, Anthony F. Daniyan	2024	1
6	Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker Blood ·Megan M. Dacek, Cherie E Saffold, Norbert Holstein, Emma Zilberman, H CHAPUT, Christopher M. Bourne, Thomas J. Gardner, L. E. Price, Laura Fućak, Anas Younes, David A. Scheinberg	2023	29
7	Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection Molecular Therapy ·Leila Peraro, Christopher M. Bourne, Megan M. Dacek, Enver Akalin, Jae H. Park, Eric L. Smith, David A. Scheinberg	2021	14
8	Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform Cancer Immunology Research ·Ron S. Gejman, Y-T Li, Martin G. Klatt, Aaron Y. Chang, Claire Y. Oh, Smita S. Chandran, 治彌松本, M.Dini Mdini, Tao Dao, Christopher A. Klebanoff, David A. Scheinberg	2020	26
9	Solving an MHC allele–specific bias in the reported immunopeptidome JCI Insight ·Martin G. Klatt, Peter Missotten, Yang Bai, Michael Guglielmo, T. Griffin Cascino, Fabian Beer, Tao Dao, David A. Scheinberg	2020	15
10	ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome Cancer Immunology Research ·Claire Y. Oh, Martin G. Klatt, Christopher M. Bourne, Tao Dao, Megan M. Dacek, Elliott J. Brea, Fabian Beer, Aaron Y. Chang, Tatyana Korontsvit, David A. Scheinberg	2019	31
11	Rejection of immunogenic tumor clones is limited by clonal fraction eLife ·Ron S. Gejman, Aaron Y. Chang, Y-T Li, Stephan Forchhammer, A. Ari Hakimi, Andrea Schietinger, David A. Scheinberg	2018	79
12	A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma Clinical Cancer Research ·Marjorie G. Zauderer, Anne S. Tsao, Tao Dao, Katherine S. Panageas, W. Victoria Lai, Andreas Rimner, Valerie W. Rusch, Prasad S. Adusumilli, Michelle S. Ginsberg, Daniel R. Gomez, David Rice, Reza J. Mehran, David A. Scheinberg, Lee M. Krug	2017	46
13	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells Cancer Immunology Research ·Elliott J. Brea, Claire Y. Oh, Eusebio Manchado, Sadna Budhu, Ron S. Gejman, George Mo, Patrizia Mondello, James E. Han, Casey A. Jarvis, David Ulmert, Qing Xiang, Aaron Y. Chang, Ralph Garippa, Taha Merghoub, Jedd D. Wolchok, Neal Rosen, Scott W. Lowe, David A. Scheinberg	2016	128
14	Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein Clinical Cancer Research ·Nicholas Veomett, Tao Dao, Hong Liu, Jingyi Xiang, Dmitry Pankov, Leonid Dubrovsky, Yao Wei, Sun‐Mi Park, Tatyana Korontsvit, Victoria Zakhaleva, Emily Casey, Michael Curcio, Michael G. Kharas, Richard J. O’Reilly, Liu C, David A. Scheinberg	2014	41
15	A High-Throughput Scintillation Proximity-Based Assay for Human DNA Ligase IV Assay and Drug Development Technologies ·N Füratsch, David Shum, Bhavneet Bhinder, Shuai Wang, Nicholas Veomett, Alan E. Tomkinson, David Y. Gin, Hakim Djaballah, David A. Scheinberg	2011	13
16	Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to Tumors Cancer Research ·Freddy E. Escorcia, Erik Henke, Michael R. McDevitt, Carlos H. Villa, Peter Smith‐Jones, Ronald G. Blasberg, Robert Benezra, David A. Scheinberg	2010	70
17	A High-Throughput Screen for Alpha Particle Radiation Protectants Assay and Drug Development Technologies ·Jonathan Seideman, David Shum, Hakim Djaballah, David A. Scheinberg	2010	9
18	Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs Cancer Research ·Mark Heaney, Jeffrey R. Gardner, Nicos Karasavvas, David W. Golde, David A. Scheinberg, Emily A. Smith, Owen A. O’Connor	2008	169
19	Immune therapy of chronic myelogenous leukemia Leukemia Research ·Robert Peter Gale, Mary M. Horowitz, Moshe Talpaz, David A. Scheinberg, Jeffrey J. Molldrem, Zihai Li, Michele Baccarani, John M. Goldman, S Tura	2005	1
20	Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics Journal of Clinical Investigation ·Avni Shah, Yuhong She, Michael J. Soskis, Christopher P. Borella, Jeffrey R. Gardner, Sarah Beisell, Benzon M. Dy, Mark Heaney, Mark R. Philips, William G. Bornmann, Francis M. Sirotnak, David A. Scheinberg	2004	83

About David A. Scheinberg

David A. Scheinberg is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Immunology, Hematology and Genetics, having authored 304 papers that have together received 17.9k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (83 papers), Monoclonal and Polyclonal Antibodies Research (81 papers), CAR-T cell therapy research (61 papers), Immunotherapy and Immune Responses (46 papers), Lymphoma Diagnosis and Treatment (23 papers), Acute Myeloid Leukemia Research (22 papers), Peptidase Inhibition and Analysis (22 papers) and Chronic Lymphocytic Leukemia Research (21 papers). The work is most often cited by research in Hematology (3.3k citations), Radiology, Nuclear Medicine and Imaging (5.6k citations), Oncology (4.5k citations), Immunology (2.9k citations) and Biochemistry (799 citations). David A. Scheinberg has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Michael R. McDevitt, Joseph G. Jurcic, Raymond P. Warrell, Ronald D. Finn, George Sgouros, Janice Gabrilove, Steven M. Larson, Dangshe Ma, Tao Dao and P. Maslak. Their work appears in journals such as Blood, Journal of Clinical Oncology, PLoS ONE, Clinical Cancer Research and OncoImmunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact